uniQure « Terug naar discussie overzicht

Wat is de waarde van uniQure?

7.835 Posts, Pagina: « 1 2 3 4 5 6 ... 285 286 287 288 289 290 291 292 293 294 295 ... 388 389 390 391 392 » | Laatste

Omlaag ↓

rationeel 22 juli 2017 16:43

quote:
Eeuwige Rijkdom schreef op 21 juli 2017 12:04:
Tot de $ 33.00 zal toch nog enige tijd duren vermoed ik. Maar deze opwaartse beweging is vast meegenomen.

Bij een paar maandse verdubbeling van de koers, kan dat snel gaan. En dan een lucratieve overname prijs;)

4...8...16...32...Overname??? 50 ???

Het is voor nu belangrijk, of de low gezet is. En verder kunnen we Crucell nog even in de herinnering roepen. Die was ook niet mals in de daling, om toch weer uit de as te herrijzen.
Good old times:)

DeZwarteRidder 22 juli 2017 16:49

quote:
cqtvld schreef op 20 juli 2017 22:10:
En boven de $8 ....en 28 cent,waar zijn onze trouwe forumleden.

De koers wordt waarschijnlijk omhoog geduwd vanwege de komende emissie.

rationeel 23 juli 2017 00:04

quote:
DeZwarteRidder schreef op 22 juli 2017 16:49:
[...]
De koers wordt waarschijnlijk omhoog geduwd vanwege de komende emissie.

Kun je ons ook nog vertellen, hoe hoog?

[verwijderd] 23 juli 2017 09:11

quote:
DeZwarteRidder schreef op 22 juli 2017 16:49:
[...]
De koers wordt waarschijnlijk omhoog geduwd vanwege de komende emissie.

DZR, dit is misleidend en hoort niet thuis op een beleggingsforum; je zakt steeds dieper.

DeZwarteRidder 23 juli 2017 15:03

Het geld vliegt de deur uit bij UniQure en ze hebben grote schulden, dus ik verwacht een emissie ergens in het 2e halfjaar.

rationeel 23 juli 2017 19:05

quote:
DeZwarteRidder schreef op 23 juli 2017 15:03:
Het geld vliegt de deur uit bij UniQure en ze hebben grote schulden, dus ik verwacht een emissie ergens in het 2e halfjaar.

En hoe hoog is de koers dan inmiddels gestegen?

Prof. Dollar 24 juli 2017 07:21

Off topic:
4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases www.4dmoleculartherapeutics.com/4d-mo...

rationeel 24 juli 2017 21:11

quote:
Prof. Dollar schreef op 24 juli 2017 07:21:
Off topic:
4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases www.4dmoleculartherapeutics.com/4d-mo...

Geweldige ontwikkelingen.

[verwijderd] 24 juli 2017 21:37

quote:
DeZwarteRidder schreef op 23 juli 2017 15:03:
Het geld vliegt de deur uit bij UniQure en ze hebben grote schulden, dus ik verwacht een emissie ergens in het 2e halfjaar.

Ooohh, het is 'jouw' verwachting.......

QLVT 24 juli 2017 22:11

Nou,nou , nou gaat weer de goeie kant op met dit aandeel...

Vitavita 28 juli 2017 16:39

Na een ongekende koersrally van bijna 93% is het tijd voor een correctiegolf.

De shorters zien hun kans schoon. Hé, zie ik daar DZR shorten, of is ie zijn wonden aan het likken.

Hoe groot en lang zal de correctie duren?

Ik denk, dat Rationeel druk in de weer is met de fibonacci.

Prof. Dollar 29 juli 2017 14:03

Uhm, Maiken Keson-Brookes (SVP and General Counsel at uniQure) maakt geen onderdeel meer uit van het management team. De Q2 medio half augustus zal wel meer duiding daarover geven. www.uniqure.com/about/management-team...

Fartknock 31 juli 2017 13:27

tools.eurolandir.com/tools/Pressrelea...

uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B

~ Company now owns full global rights to late-stage program with clinical proof-of-concept ~

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 31, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has entered into an agreement with Chiesi Group to reacquire the rights to co-develop and commercialize its hemophilia B gene therapy in Europe and other select territories and to terminate their co-development and license agreement.

"We are very pleased to reach an agreement with Chiesi to acquire back European and other territorial rights to our lead gene therapy program in hemophilia B," stated Matthew Kapusta, Chief Executive Officer of uniQure. "By regaining unencumbered, global rights to a late-stage program that has demonstrated significant clinical benefit for patients with hemophilia B, we believe uniQure is better positioned to accelerate the global clinical development plan, maximize shareholder return on our pipeline and take advantage of new potential opportunities related to the program. We are grateful for the substantial investments that Chiesi has made in AMT-060, and we have been fortunate to have them as a collaboration partner over the years."

"As we recently announced, we have made significant progress in preparing for a late-stage clinical program in hemophilia B and look forward to providing additional updates this fall," added Mr. Kapusta.

"Chiesi's decision was driven by recent changes in our strategic priorities," stated Ugo Di Francesco, Chief Executive Officer of Chiesi. "We greatly appreciate the advances uniQure has made in the development of AMT-060 over the years and sincerely wish them the best as they advance this potentially exciting gene therapy to patients. We will continue to support the transition and expect it will be relatively quick and seamless."

In 2013, uniQure and Chiesi entered into an agreement for the co-development and commercialization of a hemophilia B gene therapy in Europe and other select territories, including an equal sharing of all development related costs. Under the terms of the agreement announced today, uniQure will be responsible for all future development costs related to its hemophilia B program, including approximately $3 million of expenses in 2017 that would have otherwise been shared with Chiesi. The Company does not expect the transaction will impact its previous cash guidance, and continues to anticipate cash on hand will be sufficient to fund operations into 2019.

As a result of the transaction, uniQure expects to recognize in the third quarter of 2017 the remaining deferred revenue of approximately $14 million from non-refundable payments received from Chiesi in 2013.

Prof. Dollar 31 juli 2017 13:49

Zeg het maar: Her-verkrijgt uniQure de rechten of dumpt Chiesi het programma?

Fartknock 31 juli 2017 14:30

Anders verwoord: Wie nam het initiatief hiertoe?

T. Montana 31 juli 2017 15:09

quote:
Prof. Dollar schreef op 31 juli 2017 13:49:
Zeg het maar: Her-verkrijgt uniQure de rechten of dumpt Chiesi het programma?

Ik denk herverkrijgt en goede zaak. Chiesi was goed toen, maar niet de partner om global de strijd aan te gaan. Hoe dan ook, mooie partnering asset. De quote van Kapusta zinspeelt hier m.i. op: ... "better positioned to accelerate the global clinical development plan, maximize shareholder return on our pipeline and take advantage of new potential opportunities related to the program.

Prof. Dollar 31 juli 2017 17:34

quote:
T. Montana schreef op 31 juli 2017 15:09:
[...]

Ik denk herverkrijgt en goede zaak. Chiesi was goed toen, maar niet de partner om global de strijd aan te gaan. Hoe dan ook, mooie partnering asset. De quote van Kapusta zinspeelt hier m.i. op: ... "better positioned to accelerate the global clinical development plan, maximize shareholder return on our pipeline and take advantage of new potential opportunities related to the program.

Dat Chiesi niet de big pharma is waarmee de wereld wordt veroverd daarin kan ik mij vinden. Aan welke 'potential opportunities' die nota bene gerelateerd zijn aan het programma zouden ze denken?

T. Montana 31 juli 2017 18:56

quote:
Prof. Dollar schreef op 31 juli 2017 17:34:
[...]
Dat Chiesi niet de big pharma is waarmee de wereld wordt veroverd daarin kan ik mij vinden. Aan welke 'potential opportunities' die nota bene gerelateerd zijn aan het programma zouden ze denken?

Voor het zingen de Chiesi uit. Biomarin, Baxter?

de tuinman 1 augustus 2017 12:23

www.fiercebiotech.com/biotech/chiesi-...

DeZwarteRidder 1 augustus 2017 12:28

quote:
de tuinman schreef op 1 augustus 2017 12:23:
www.fiercebiotech.com/biotech/chiesi-...

Dit bericht klinkt heel anders en volgens mij meer in overeenstemming met de harde waarheid:
-----------------------------------------------------------
Chiesi dumps uniQure’s hemophilia B gene therapy
by Nick Paul Taylor | Aug 1, 2017 4:48am
Chiesi's research center in Parma, Italy

Chiesi has cut its ties to uniQure’s hemophilia B gene therapy. The split gives uniQure full rights to AMT-060 but leaves it without a partner to cofund R&D as it closes in on the start of a pivotal trial.

Italian drugmaker Chiesi picked up the rights to commercialize AMT-060 in certain markets in 2013 as part of a deal that also gave it a piece of Glybera, the gene therapy that made history by coming to market in Europe only to flop commercially. Chiesi backed out of the Glybera agreement earlier this year and has now completed its split from uniQure by terminating the hemophilia B pact.

Amsterdam, the Netherlands-based uniQure framed the termination as it reacquiring the rights to AMT-060, rather than Chiesi dumping the program. But as the deal will see money transfer from Chiesi to uniQure and the former stated a shift in priorities prompted it to sever ties to AMT-060, it seems clear the Italian drugmaker wanted to exit the agreement.

That leaves uniQure facing the prospect of taking AMT-060 into a pivotal trial without the financial support of a partner. Chiesi and uniQure have evenly shared R&D costs since 2013. The loss of the support of Chiesi will add $3 million to uniQure’s outlay this year, although the Dutch biotech still thinks it has enough cash to take it into 2019.

After a trying time on public markets dotted with stock drops following unfavorable comparisons to Spark Therapeutics’ rival hemophilia B program, uniQure is less well equipped to raise more money than in the past. But uniQure CEO Matthew Kapusta spun the regaining of full rights to the gene therapy as a boost for the company.

“We believe uniQure is better positioned to accelerate the global clinical development plan, maximize shareholder return on our pipeline and take advantage of new potential opportunities related to the program,” Kapusta said in a statement.

If the “potential opportunities” are to include a deal covering AMT-060, uniQure must persuade a potential partner of the merits of its asset. UniQure has sought to focus attention on the durable clinical benefits associated with AMT-060 but investors have fixated on Spark’s clear advantage in terms of Factor IX activity.

7.835 Posts, Pagina: « 1 2 3 4 5 6 ... 285 286 287 288 289 290 291 292 293 294 295 ... 388 389 390 391 392 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 942,28 -4,78 -0,50% 18:05


Germany40^	22.431,00	-1,81%
BEL 20	4.370,16	-0,99%
Europe50^	5.455,79	-1,41%
US30^	44.567,50	+0,05%
Nasd100^	22.219,80	+0,25%
US500^	6.146,73	+0,31%
Japan225^	39.004,80	-0,80%
Gold spot	2.931,94	-0,11%
EUR/USD	1,0425	-0,25%
WTI	72,12	+0,59%